Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients

Core Viewpoint - Hemostemix Inc. has launched an upgraded corporate website powered by HubSpot to enhance marketing and sales efforts for its VesCell™ (ACP-01) stem cell therapy, aimed at patients with life-threatening conditions who have exhausted standard treatment options [1][2][12]. Group 1: Website Enhancements - The new website integrates HubSpot's infrastructure, transitioning from a static presence to an interactive marketing and CRM platform, which includes automated workflows and AI engagement tools [8][17]. - Key enhancements include automated administrative workflows, AI-driven patient and clinician engagement, and real-time analytics for operational monitoring [8][10][16]. Group 2: Marketing and Sales Strategy - The upgraded platform is designed to accelerate the adoption of ACP-01 in Florida and other jurisdictions, focusing on streamlined lead generation, efficient patient intake, and targeted outreach to clinical partners [4][5][6]. - The marketing team has expanded to focus on specific medical specialties, such as vascular surgeons and cardiologists, to enhance outreach efforts [6][16]. Group 3: Strategic Impact and Future Outlook - The upgraded websites are a strategic cornerstone in Hemostemix's commercialization roadmap, supporting rapid patient intake and compliance with evolving regulations [12][14]. - The CEO highlighted that this transition amplifies the impact of recent financings and allows for real-time tracking of marketing and sales activities [14][16].